Methylene blue and ascorbate interfere with the accurate determination of the kinetic properties of IDO2.

FEBS J

Arterial Inflammation and Redox Biology Group, Heart Research Institute, Newtown, NSW, Australia.

Published: August 2021

Indoleamine 2,3-dioxygenases (IDOs) catalyze the oxidative cleavage of L-tryptophan (Trp) to N-formylkynurenine. Two IDOs, IDO1 and IDO2, are present in vertebrates. IDO1 is a high-affinity Trp-degrading enzyme involved in several physiological processes. By comparison, IDO2 generally has been reported to have low affinity (high K -value) for Trp, and the enzyme's in vivo function remains unclear. Using IDOs from different species, we show that compared with ferrous-oxy (Fe -O ) IDO1, Fe -O IDO2 is substantially more stable and engages in multiple turnovers of the reaction in the absence of a reductant. Without reductant, Fe -O IDO2 showed K -values in the range of 80-356 μM, that is, values substantially lower than reported previously and close to the physiological concentrations of Trp. Methylene blue and ascorbate (Asc), used commonly as the reducing system for IDO activity determination, significantly affected the enzymatic activity of IDO2: In combination, the two reductants increased the apparent K - and k -values 8- to 117-fold and 2-fold, respectively. Asc alone both activated and inhibited IDO2 by acting as a source of electrons and as a weak competitive inhibitor, respectively. In addition, ferric (Fe ) IDO1 and IDO2 exhibited weak dioxygenase activity, similar to tryptophan 2,3-dioxygenase. Our results shed new light in the enzymatic activity of IDO2, and they support the view that this isoform of IDO also participates in the metabolism of Trp in vivo.

Download full-text PDF

Source
http://dx.doi.org/10.1111/febs.15806DOI Listing

Publication Analysis

Top Keywords

ido1 ido2
12
ido2
9
methylene blue
8
blue ascorbate
8
enzymatic activity
8
activity ido2
8
ascorbate interfere
4
interfere accurate
4
accurate determination
4
determination kinetic
4

Similar Publications

Article Synopsis
  • Substance use disorder (SUD) is a major public health issue in the U.S., linked to rising overdose deaths and prescription drug misuse, highlighting the need to explore its molecular and genetic roots.
  • The study utilized the All of Us cohort to analyze genetic variants in four genes related to the kynurenine pathway across six groups, including various types of substance use disorders.
  • Results indicated significant genetic variations in 14 out of 18 polymorphisms, with the cocaine group showing the highest number of significant variants, suggesting possible genetic predictors for increased susceptibility to SUD.
View Article and Find Full Text PDF

The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2).

Cells

November 2024

Section of Pharmacology, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy.

Indoleamine 2,3-dioxygenase 1 () and originated from gene duplication before vertebrate divergence. While IDO1 has a well-defined role in immune regulation, the biological role of IDO2 remains unclear. Discovered in 2007, is located near the gene.

View Article and Find Full Text PDF

Gene expression of kynurenine pathway enzymes in depression and following electroconvulsive therapy.

Acta Neuropsychiatr

October 2024

Neuropsychopharmacology Research Group, School of Pharmacy and Pharmaceutical Sciences & Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland.

Article Synopsis
  • This study explored how the expression of kynurenine pathway (KP) enzymes in the blood is affected in patients with depression compared to healthy controls and post-electroconvulsive therapy (ECT).
  • Results showed that certain KP enzymes were lower in patients with depression, but these findings weren’t statistically significant after accounting for other factors; ECT didn't change KP enzyme expression.
  • The study suggests that further research is needed to see if KP measures can effectively help in diagnosing depression and predicting responses to antidepressant treatments.
View Article and Find Full Text PDF

Neuroactive Kynurenines as Pharmacological Targets: New Experimental Tools and Exciting Therapeutic Opportunities.

Pharmacol Rev

October 2024

Department of Pharmacology, Physiology, and Neuroscience, University of South Carolina School of Medicine, Columbia, South Carolina (A.P.); Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland (R.S.); and Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (S.E.)

Both preclinical and clinical studies implicate functional impairments of several neuroactive metabolites of the kynurenine pathway (KP), the major degradative cascade of the essential amino acid tryptophan in mammals, in the pathophysiology of neurologic and psychiatric diseases. A number of KP enzymes, such as tryptophan 2,3-dioxygenase (TDO2), indoleamine 2,3-dioxygenases (IDO1 and IDO2), kynurenine aminotransferases (KATs), kynurenine 3-monooxygenase (KMO), 3-hydroxyanthranilic acid oxygenase (3-HAO), and quinolinic acid phosphoribosyltransferase (QPRT), control brain KP metabolism in health and disease and are therefore increasingly considered to be promising targets for the treatment of disorders of the nervous system. Understanding the distribution, cellular expression, and regulation of KP enzymes and KP metabolites in the brain is therefore critical for the conceptualization and implementation of successful therapeutic strategies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!